701
|
Jiang Y, Fang RH, Zhang L. Biomimetic Nanosponges for Treating Antibody-Mediated Autoimmune Diseases. Bioconjug Chem 2018; 29:870-877. [PMID: 29357234 DOI: 10.1021/acs.bioconjchem.7b00814] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Autoimmune diseases are characterized by overactive immunity, where the body's defense system launches an attack against itself. If left unchecked, this can result in the destruction of healthy tissue and significantly affect patient well-being. In the case of type II autoimmune hypersensitivities, autoreactive antibodies attack the host's own cells or extracellular matrix. Current clinical treatment modalities for managing this class of disease are generally nonspecific and face considerable limitations. In this Topical Review, we cover emerging therapeutic strategies, with an emphasis on novel nanomedicine platforms. Specifically, the use of biomimetic cell membrane-coated nanosponges that are capable of specifically binding and neutralizing pathological antibodies will be explored. There is significant untapped potential in the application of nanotechnology for the treatment of autoimmune diseases, and continued development along this line may help to eventually change the clinical landscape.
Collapse
Affiliation(s)
- Yao Jiang
- Department of NanoEngineering and Moores Cancer Center , University of California San Diego , La Jolla , California 92093 , United States
| | - Ronnie H Fang
- Department of NanoEngineering and Moores Cancer Center , University of California San Diego , La Jolla , California 92093 , United States
| | - Liangfang Zhang
- Department of NanoEngineering and Moores Cancer Center , University of California San Diego , La Jolla , California 92093 , United States
| |
Collapse
|
702
|
Fisusi FA, Schätzlein AG, Uchegbu IF. Nanomedicines in the treatment of brain tumors. Nanomedicine (Lond) 2018; 13:579-583. [PMID: 29376468 DOI: 10.2217/nnm-2017-0378] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Affiliation(s)
- Funmilola A Fisusi
- UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1N 1AX, UK.,Drug Research & Production Unit, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria
| | - Andreas G Schätzlein
- UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1N 1AX, UK.,Nanomerics Ltd., New Bridge Street House, 30-34 New Bridge Street, London, EC4V 6BJ, UK
| | - Ijeoma F Uchegbu
- UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1N 1AX, UK.,Nanomerics Ltd., New Bridge Street House, 30-34 New Bridge Street, London, EC4V 6BJ, UK
| |
Collapse
|
703
|
Hartshorn CM, Bradbury MS, Lanza GM, Nel AE, Rao J, Wang AZ, Wiesner UB, Yang L, Grodzinski P. Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS NANO 2018; 12:24-43. [PMID: 29257865 PMCID: PMC6589353 DOI: 10.1021/acsnano.7b05108] [Citation(s) in RCA: 148] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Ongoing research into the application of nanotechnology for cancer treatment and diagnosis has demonstrated its advantages within contemporary oncology as well as its intrinsic limitations. The National Cancer Institute publishes the Cancer Nanotechnology Plan every 5 years since 2005. The most recent iteration helped codify the ongoing basic and translational efforts of the field and displayed its breadth with several evolving areas. From merely a technological perspective, this field has seen tremendous growth and success. However, an incomplete understanding of human cancer biology persists relative to the application of nanoscale materials within contemporary oncology. As such, this review presents several evolving areas in cancer nanotechnology in order to identify key clinical and biological challenges that need to be addressed to improve patient outcomes. From this clinical perspective, a sampling of the nano-enabled solutions attempting to overcome barriers faced by traditional therapeutics and diagnostics in the clinical setting are discussed. Finally, a strategic outlook of the future is discussed to highlight the need for next-generation cancer nanotechnology tools designed to address critical gaps in clinical cancer care.
Collapse
Affiliation(s)
- Christopher M Hartshorn
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States
- Corresponding Author,
| | - Michelle S Bradbury
- Department of Radiology and Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, New York, New York, 10065, United States
| | - Gregory M Lanza
- Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri 63108, United States
| | - Andre E Nel
- Division of NanoMedicine, Department of Medicine, and California NanoSystems Institute, University of California, Los Angeles, California 90095, United States
| | - Jianghong Rao
- Department of Radiology and Molecular Imaging Program at Stanford (MIPS), Stanford School of Medicine, Stanford, California 94305, United States
| | - Andrew Z. Wang
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
| | - Ulrich B Wiesner
- Department of Materials Science and Engineering, Cornell University, Ithaca, New York 14843, United States
| | - Lily Yang
- Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, United States
| | - Piotr Grodzinski
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States
- Corresponding Author,
| |
Collapse
|
704
|
Mignani S, Rodrigues J, Tomas H, Zablocka M, Shi X, Caminade AM, Majoral JP. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev 2018; 47:514-532. [PMID: 29154385 DOI: 10.1039/c7cs00550d] [Citation(s) in RCA: 139] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
For the first time, an overview of dendrimers in combination with natural products and analogues as anti-cancer agents is presented. This reflects the development of drug delivery systems, such as dendrimers, to tackle cancers. The most significant advantages of using dendrimers in nanomedicine are their high biocompatibility, good water solubility, and their entry - with or without encapsulated, complexed or conjugated drugs - through an endocytosis process. This strategy has accelerated over the years in order to develop nanosystems as nanocarriers, to decrease the intrinsic toxicity of anti-cancer agents, to decrease the drug side effects, to increase the efficacy of the treatment, and consequently to improve patient compliance.
Collapse
Affiliation(s)
- Serge Mignani
- Université Paris Descartes, PRES Sorbonne Paris Cité, CNRS UMR 860, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, 45, rue des Saints Peres, 75006, Paris, France
| | | | | | | | | | | | | |
Collapse
|
705
|
Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small. J Control Release 2018; 272:159-168. [PMID: 29355619 DOI: 10.1016/j.jconrel.2018.01.009] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 01/11/2018] [Accepted: 01/11/2018] [Indexed: 12/30/2022]
Abstract
Nanotechnology ushered the field of medicine in to a new era. Miniaturization, increased surface area, and the unique physicochemical properties in the nano dimension were explored for new applications. Pharmaceutical industry picked up the technology and early success came fast for oral drug delivery through improvement in dissolution properties of the active molecules. Many products were launched using the nanocrystal technology on the oral side. Further development of polymeric nanoparticles led to wide spread research of nanocarriers for parenteral delivery. While considerable efforts have gone in the last two decades for testing nanoparticles for tumor targeting, delivery into tumors has remained challenging and suboptimal. Inadequate in vivo models that didn't accurately reflect the age and vascularity of human tumors, and inability to reproducibly target therapeutic drugs to the tissue of interest due to intrinsic biodistribution of the particles and hence side effects, limited the number of studies that advanced to the clinic. Our article addresses the questions commonly asked by scientific researchers in nanomedicine: "Has nanoparticle technology yielded on its initial promise that scientists predicted towards improving therapeutic index and avoid toxicity by delivering molecules to target tissues or was it more of wishful thinking that had several roadblocks?" We answer this question by linking the relevance of nanoparticles to cancer immunotherapy. The advent of immunotherapy has begun to show the potential applicability of nanoparticles in a different light, to target the immune system. In this approach, nanoparticles may positively influence the immune system rather than create the targeted "magic bullet". Utilizing the intrinsic properties of nanoparticles for immune targeting as opposed to targeting the tumor can bring about a positive difference due to the underlying complex cancer mechanisms that can potentially overlap with the heterogeneous biodistribution of nanoparticles towards improving the acquired and innate immune responses. In this review, we have followed the progress of nanotechnology in pharmaceutical applications with key insights from oral and parenteral drug delivery, and how to modify our thinking to better utilize nanoparticles for immuno-oncology. In contrast to conventional "local" tumor targeting by nanoparticles, we propose a new mechanism whereby nanoparticles trigger priming of the T cells towards tumor destruction. The heterogenous biodistribution of nanoparticles lends itself to stimulating immune cells systemically in a "global" manner and with the right therapeutic combinations will be able to trigger tumor antigens to continually activate, retain memory effects and destroy tumor cells.
Collapse
|
706
|
Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 2018; 9:21. [PMID: 29343814 PMCID: PMC5833697 DOI: 10.1038/s41419-017-0072-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2017] [Revised: 08/10/2017] [Accepted: 08/17/2017] [Indexed: 01/26/2023]
Abstract
Estrogen receptor-α positive (ERα+) breast cancer accounts for approximately 70–80% of the nearly 25,0000 new cases of breast cancer diagnosed in the US each year. Endocrine-targeted therapies (those that block ERα activity) serve as the first line of treatment in most cases. Despite the proven benefit of endocrine therapies, however, ERα+ breast tumors can develop resistance to endocrine therapy, causing disease progression or relapse, particularly in the metastatic setting. Anti-apoptotic Bcl-2 family proteins enhance breast tumor cell survival, often promoting resistance to targeted therapies, including endocrine therapies. Herein, we investigated whether blockade of anti-apoptotic Bcl-2 family proteins could sensitize luminal breast cancers to anti-estrogen treatment. We used long-term estrogen deprivation (LTED) of human ERα+ breast cancer cell lines, an established model of sustained treatment with and acquired resistance to aromatase inhibitors (AIs), in combination with Bcl-2/Bcl-xL inhibition (ABT-263), finding that ABT-263 induced only limited tumor cell killing in LTED-selected cells in culture and in vivo. Interestingly, expression and activity of the Bcl-2-related factor Mcl-1 was increased in LTED cells. Genetic Mcl-1 ablation induced apoptosis in LTED-selected cells, and potently increased their sensitivity to ABT-263. Increased expression and activity of Mcl-1 was similarly seen in clinical breast tumor specimens treated with AI + the selective estrogen receptor downregulator fulvestrant. Delivery of Mcl-1 siRNA loaded into polymeric nanoparticles (MCL1 si-NPs) decreased Mcl-1 expression in LTED-selected and fulvestrant-treated cells, increasing tumor cell death and blocking tumor cell growth. These findings suggest that Mcl-1 upregulation in response to anti-estrogen treatment enhances tumor cell survival, decreasing response to therapeutic treatments. Therefore, strategies blocking Mcl-1 expression or activity used in combination with endocrine therapies would enhance tumor cell death.
Collapse
Affiliation(s)
- Michelle M Williams
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Linus Lee
- Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN, USA
| | - Thomas Werfel
- Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN, USA
| | - Meghan M Morrison Joly
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Donna J Hicks
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Bushra Rahman
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - David Elion
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Courtney McKernan
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Violeta Sanchez
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Monica V Estrada
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Suleiman Massarweh
- Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - Richard Elledge
- Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX, USA
| | - Craig Duvall
- Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN, USA
| | - Rebecca S Cook
- Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA. .,Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN, USA. .,The Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
| |
Collapse
|
707
|
Nordgård CT, Draget KI. Co association of mucus modulating agents and nanoparticles for mucosal drug delivery. Adv Drug Deliv Rev 2018; 124:175-183. [PMID: 29307632 DOI: 10.1016/j.addr.2018.01.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 11/26/2017] [Accepted: 01/02/2018] [Indexed: 01/27/2023]
Abstract
Nanoparticulate drug delivery systems (nDDS) offer a variety of options when it comes to routes of administration. One possible path is crossing mucosal barriers, such as in the airways and in the GI tract, for systemic distribution or local treatment. The main challenge with this administration route is that the size and surface properties of the nanoparticles, as opposed to small molecular drugs, very often results in mucosal capture, immobilization and removal, which in turn results in a very low bioavailability. Strategies to overcome this challenge do exist, like surface 'stealth' modification with PEG. Here we review an alternative or supplemental strategy, co-association of mucus modulating agents with the nDDS to improve bioavailability, where the nDDS may be surface modified or unmodified. This contribution presents some examples on how possible co-association systems may be achieved, using currently marketed mucolytic drugs, alternative formulations or novel agents.
Collapse
Affiliation(s)
- Catherine Taylor Nordgård
- NOBIPOL, Department of Biotechnology and Food Science, Norwegian University of Science and Technology NTNU, 7491 Trondheim, Norway.
| | - Kurt I Draget
- NOBIPOL, Department of Biotechnology and Food Science, Norwegian University of Science and Technology NTNU, 7491 Trondheim, Norway.
| |
Collapse
|
708
|
Dilnawaz F, Acharya S, Sahoo SK. Recent trends of nanomedicinal approaches in clinics. Int J Pharm 2018; 538:263-278. [PMID: 29339248 DOI: 10.1016/j.ijpharm.2018.01.016] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Revised: 01/05/2018] [Accepted: 01/05/2018] [Indexed: 12/20/2022]
Abstract
Nanotechnology has become the indispensable cutting edge science providing solutions to many problems associated with human being. The application of nanotechnology associated to human health "nanomedicine" has revolutionized the drug delivery system by providing improved pharmacological and therapeutic properties of drugs. These advantageous effects of drug loaded nanocarrier systems are embraced by the pharmaceutical industries for the development of different effective nanocarriers. Currently, several drug loaded nanoformulations are approved by the Food and Drug Administration (FDA), and some of them are undergoing clinical trials for the human use. In this review, we have discussed the progress achieved so far for various drug loaded nanoformulations along with few emerging nanoformulations that are about to enter into clinical trials.
Collapse
Affiliation(s)
- Fahima Dilnawaz
- Laboratory of Nanomedicine, Institute of Life Sciences, Bhubaneswar 751023, Odisha, India
| | - Sarbari Acharya
- Laboratory of Nanomedicine, Institute of Life Sciences, Bhubaneswar 751023, Odisha, India
| | - Sanjeeb Kumar Sahoo
- Laboratory of Nanomedicine, Institute of Life Sciences, Bhubaneswar 751023, Odisha, India.
| |
Collapse
|
709
|
Homyak CC, Fernandez A, Touve MA, Zhao B, Anson F, Hardy JA, Vachet RW, Gianneschi NC, Ross JL, Thayumanavan S. Lipogels for Encapsulation of Hydrophilic Proteins and Hydrophobic Small Molecules. Biomacromolecules 2018; 19:132-140. [PMID: 29141403 PMCID: PMC6326177 DOI: 10.1021/acs.biomac.7b01300] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Lipid-polymer hybrid materials have the potential to exhibit enhanced stability and loading capabilities in comparison to parent liposome or polymer materials. However, complexities lie in formulating and characterizing such complex nanomaterials. Here we describe a lipid-coated polymer gel (lipogel) formulated using a single-pot methodology, where self-assembling liposomes template a UV-curable polymer gel core. Using fluorescently labeled lipids, protein, and hydrophobic molecules, we characterized their formation, purification, stability, and encapsulation efficiency via common instrumentation methods such as dynamic light scattering (DLS), matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS), UV-vis spectroscopy, fluorescence spectroscopy, and single-particle total internal reflection fluorescence (TIRF) microscopy. In addition, we confirmed that these dual-guest-loaded lipogels are stable in solution for several months. The simplicity of this complete aqueous formation and noncovalent dual-guest encapsulation holds potential as a tunable nanomaterial scaffold.
Collapse
Affiliation(s)
- Celia C. Homyak
- Department of Chemistry, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
| | - Ann Fernandez
- Department of Chemistry, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
| | - Mollie A. Touve
- Department of Chemistry, Northwestern University, Evanston, IL 60208
| | - Bo Zhao
- Department of Chemistry, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
| | - Francesca Anson
- Department of Chemistry, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
| | - Jeanne A. Hardy
- Department of Chemistry, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
- Molecular and Cellular Biology Graduate Program, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
- Center for Bioactive Delivery, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
| | - Richard W. Vachet
- Department of Chemistry, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
- Molecular and Cellular Biology Graduate Program, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
- Center for Bioactive Delivery, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
| | - Nathan C. Gianneschi
- Department of Chemistry, Northwestern University, Evanston, IL 60208
- Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093
| | - Jennifer L. Ross
- Molecular and Cellular Biology Graduate Program, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
- Center for Bioactive Delivery, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
- Department of Physics, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
| | - S. Thayumanavan
- Department of Chemistry, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
- Molecular and Cellular Biology Graduate Program, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
- Center for Bioactive Delivery, Institute for Applied Life Sciences University of Massachusetts, Amherst, MA 01003
| |
Collapse
|
710
|
Ferreira H, Martins A, Alves da Silva ML, Amorim S, Faria S, Pires RA, Reis RL, Neves NM. The functionalization of natural polymer-coated gold nanoparticles to carry bFGF to promote tissue regeneration. J Mater Chem B 2018; 6:2104-2115. [DOI: 10.1039/c7tb03273k] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A schematic of the preparation of natural polymer-coated AuNPs for monitoring tissue regeneration stimulated by bFGF.
Collapse
Affiliation(s)
- Helena Ferreira
- 3B's Research Group – Biomaterials
- Biodegradables and Biomimetics
- Department of Polymer Engineering
- University of Minho
- Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine
| | - Albino Martins
- 3B's Research Group – Biomaterials
- Biodegradables and Biomimetics
- Department of Polymer Engineering
- University of Minho
- Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine
| | - Marta L. Alves da Silva
- 3B's Research Group – Biomaterials
- Biodegradables and Biomimetics
- Department of Polymer Engineering
- University of Minho
- Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine
| | - Sara Amorim
- 3B's Research Group – Biomaterials
- Biodegradables and Biomimetics
- Department of Polymer Engineering
- University of Minho
- Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine
| | - Susana Faria
- Department of Mathematics for Science and Technology
- Research CMAT
- University of Minho
- 4800-058 Guimarães
- Portugal
| | - Ricardo A. Pires
- 3B's Research Group – Biomaterials
- Biodegradables and Biomimetics
- Department of Polymer Engineering
- University of Minho
- Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine
| | - Rui L. Reis
- 3B's Research Group – Biomaterials
- Biodegradables and Biomimetics
- Department of Polymer Engineering
- University of Minho
- Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine
| | - Nuno M. Neves
- 3B's Research Group – Biomaterials
- Biodegradables and Biomimetics
- Department of Polymer Engineering
- University of Minho
- Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine
| |
Collapse
|
711
|
Westmeier D, Hahlbrock A, Reinhardt C, Fröhlich-Nowoisky J, Wessler S, Vallet C, Pöschl U, Knauer SK, Stauber RH. Nanomaterial–microbe cross-talk: physicochemical principles and (patho)biological consequences. Chem Soc Rev 2018; 47:5312-5337. [DOI: 10.1039/c6cs00691d] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
NPs’ characteristics impact their spontaneous binding to microbes, which may affect the (patho)biological identity of both NP and microbes.
Collapse
Affiliation(s)
- D. Westmeier
- Department of Nanobiomedicine/ENT
- University Medical Center of Mainz
- 55101 Mainz
- Germany
| | - A. Hahlbrock
- Department of Nanobiomedicine/ENT
- University Medical Center of Mainz
- 55101 Mainz
- Germany
| | - C. Reinhardt
- Center for Thrombosis and Hemostasis
- University Medical Center Mainz
- 55101 Mainz
- Germany
| | - J. Fröhlich-Nowoisky
- Multiphase Chemistry Department
- Max Planck Institute for Chemistry
- 55128 Mainz
- Germany
| | - S. Wessler
- Department of Molecular Biology
- Paris-Lodron University of Salzburg
- A-5020 Salzburg
- Austria
| | - C. Vallet
- Institute for Molecular Biology
- CENIDE
- University Duisburg-Essen
- 45117 Essen
- Germany
| | - U. Pöschl
- Multiphase Chemistry Department
- Max Planck Institute for Chemistry
- 55128 Mainz
- Germany
| | - S. K. Knauer
- Institute for Molecular Biology
- CENIDE
- University Duisburg-Essen
- 45117 Essen
- Germany
| | - R. H. Stauber
- Department of Nanobiomedicine/ENT
- University Medical Center of Mainz
- 55101 Mainz
- Germany
| |
Collapse
|
712
|
Mathiyazhakan M, Wiraja C, Xu C. A Concise Review of Gold Nanoparticles-Based Photo-Responsive Liposomes for Controlled Drug Delivery. NANO-MICRO LETTERS 2018; 10:10. [PMID: 30393659 PMCID: PMC6199057 DOI: 10.1007/s40820-017-0166-0] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 10/09/2017] [Indexed: 05/18/2023]
Abstract
The focus of drug delivery is shifting toward smart drug carriers that release the cargo in response to a change in the microenvironment due to an internal or external trigger. As the most clinically successful nanosystem, liposomes naturally come under the spotlight of this trend. This review summarizes the latest development about the design and construction of photo-responsive liposomes with gold nanoparticles for the controlled drug release. Alongside, we overview the mechanism involved in this process and the representative applications.
Collapse
Affiliation(s)
- Malathi Mathiyazhakan
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, Singapore, 637459, Singapore
| | - Christian Wiraja
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, Singapore, 637459, Singapore
| | - Chenjie Xu
- School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, Singapore, 637459, Singapore.
| |
Collapse
|
713
|
Bharadwaj VN, Nguyen DT, Kodibagkar VD, Stabenfeldt SE. Nanoparticle-Based Therapeutics for Brain Injury. Adv Healthc Mater 2018; 7:10.1002/adhm.201700668. [PMID: 29034608 PMCID: PMC5903677 DOI: 10.1002/adhm.201700668] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Revised: 07/06/2017] [Indexed: 12/18/2022]
Abstract
Brain injuries affect a large patient population with major physical and emotional suffering for patients and their relatives; at a significant cost to the society. Effective diagnostic and therapeutic options available for brain injuries are limited by the complex brain injury pathology involving blood-brain barrier (BBB). Brain injuries, including ischemic stroke and brain trauma, initiate BBB opening for a short period of time, which is followed by a second reopening for an extended time. The leaky BBB and/or the alterations in the receptor expression on BBB may provide opportunities for therapeutic delivery via nanoparticles (NPs). The approaches for therapeutic interventions via NP delivery are aimed at salvaging the pericontusional/penumbra area for possible neuroprotection and neurovascular unit preservation. The focus of this progress report is to provide a survey of NP strategies employed in cerebral ischemia and brain trauma and finally provide insights for improved NP-based diagnostic/treatment approaches.
Collapse
Affiliation(s)
- Vimala N. Bharadwaj
- School of Biological and Health Systems Engineering, Arizona State University, PO Box 879709, Tempe, AZ 85287, United States
| | - Duong T. Nguyen
- School of Biological and Health Systems Engineering, Arizona State University, PO Box 879709, Tempe, AZ 85287, United States
| | - Vikram D. Kodibagkar
- School of Biological and Health Systems Engineering, Arizona State University, PO Box 879709, Tempe, AZ 85287, United States
| | - Sarah E. Stabenfeldt
- School of Biological and Health Systems Engineering, Arizona State University, PO Box 879709, Tempe, AZ 85287, United States
| |
Collapse
|
714
|
Mignani S, Rodrigues J, Tomas H, Zablocka M, Shi X, Caminade AM, Majoral JP. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev 2018. [DOI: https://doi.org/10.1039/c7cs00550d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Overview of the use of dendrimers in combination with encapsulated and conjugated natural products and analogues as anti-cancer agents.
Collapse
Affiliation(s)
- Serge Mignani
- Université Paris Descartes, PRES Sorbonne Paris Cité, CNRS UMR 860, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique
- Paris
- France
- CQM – Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada
- Funchal
| | - João Rodrigues
- CQM – Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada
- Funchal
- Portugal
- School of Materials Science and Engineering/Center for Nano Energy Materials, Northwestern Polytechnical University
- Xi’an
| | - Helena Tomas
- CQM – Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada
- Funchal
- Portugal
| | - Maria Zablocka
- Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences
- 90-363 Lodz
- Poland
| | - Xiangyang Shi
- CQM – Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada
- Funchal
- Portugal
- State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University
- Shanghai 201620
| | - Anne-Marie Caminade
- Laboratoire de Chimie de Coordination du CNRS
- 31077 Toulouse Cedex 4
- France
- Université de Toulouse, UPS, INPT
- 31077 Toulouse Cedex
| | - Jean-Pierre Majoral
- Laboratoire de Chimie de Coordination du CNRS
- 31077 Toulouse Cedex 4
- France
- Université de Toulouse, UPS, INPT
- 31077 Toulouse Cedex
| |
Collapse
|
715
|
Esser L, Lengkeek NA, Moffat BA, Vu MN, Greguric I, Quinn JF, Davis TP, Whittaker MR. A tunable one-pot three-component synthesis of an125I and Gd-labelled star polymer nanoparticle for hybrid imaging with MRI and nuclear medicine. Polym Chem 2018. [DOI: 10.1039/c8py00621k] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Bimodal radioiodine/Gd labelled polymeric nanoparticles prepared using a versatile one-step three-component click reaction.
Collapse
Affiliation(s)
- Lars Esser
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| | - Nigel A. Lengkeek
- Australian Nuclear Science and Technology Organisation (ANSTO)
- Kirrawee DC
- Australia
| | | | - Mai N. Vu
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| | - Ivan Greguric
- Australian Nuclear Science and Technology Organisation (ANSTO)
- Kirrawee DC
- Australia
| | - John F. Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| | - Thomas P. Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| | - Michael R. Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| |
Collapse
|
716
|
Picco AS, Ferreira LF, Liberato MS, Mondo GB, Cardoso MB. Freeze-drying of silica nanoparticles: redispersibility toward nanomedicine applications. Nanomedicine (Lond) 2018; 13:179-190. [DOI: 10.2217/nnm-2017-0280] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: To study freeze-drying of silica nanoparticles (SiO2NPs) in order to find suitable conditions to produce lyophilized powders with no aggregation after resuspension and storage. Methods: SiO2NPs were synthesized using a Stöber-based procedure, and characterized by scanning electron microscopy, dynamic light scattering and nitrogen adsorption/desorption isotherms. SiO2NPs hydrodynamic diameters were compared prior and after freeze-drying in the presence/absence of carbohydrate protectants. Results: Glucose was found to be the most suitable protectant against the detrimental effects of lyophilization. The minimum concentration of carbohydrate required to effectively protect SiO2NPs from aggregation during freeze-drying is influenced by the nanoparticle's size and texture. Negligible aggregation was observed during storage. Conclusion: Carbohydrates can be used during SiO2NPs freeze-drying process to obtain redispersable solids that maintain original sizes without residual aggregation.
Collapse
Affiliation(s)
- Agustin S Picco
- Laboratório Nacional de Nanotecnologia (LNNano)/Laboratório Nacionalde Luz Síncrotron (LNLS), Centro Nacional de Pesquisa em Energia e Materiais(CNPEM), CEP 13083-970, Caixa Postal 6192, Campinas, SP, Brasil
| | - Larissa F Ferreira
- Laboratório Nacional de Nanotecnologia (LNNano)/Laboratório Nacionalde Luz Síncrotron (LNLS), Centro Nacional de Pesquisa em Energia e Materiais(CNPEM), CEP 13083-970, Caixa Postal 6192, Campinas, SP, Brasil
- Programa de Pós-Graduação em Biotecnociência, Universidade Federal do ABC, CEP 09210-580, Santo André, Brasil
| | - Michelle S Liberato
- Laboratório Nacional de Nanotecnologia (LNNano)/Laboratório Nacionalde Luz Síncrotron (LNLS), Centro Nacional de Pesquisa em Energia e Materiais(CNPEM), CEP 13083-970, Caixa Postal 6192, Campinas, SP, Brasil
| | - Gabriela B Mondo
- Laboratório Nacional de Nanotecnologia (LNNano)/Laboratório Nacionalde Luz Síncrotron (LNLS), Centro Nacional de Pesquisa em Energia e Materiais(CNPEM), CEP 13083-970, Caixa Postal 6192, Campinas, SP, Brasil
- Instituto de Química (IQ), Universidade Estadualde Campinas [GBM1], CEP 13083-970, Caixa Postal 6154, Campinas, SP, Brasil
| | - Mateus B Cardoso
- Laboratório Nacional de Nanotecnologia (LNNano)/Laboratório Nacionalde Luz Síncrotron (LNLS), Centro Nacional de Pesquisa em Energia e Materiais(CNPEM), CEP 13083-970, Caixa Postal 6192, Campinas, SP, Brasil
- Programa de Pós-Graduação em Biotecnociência, Universidade Federal do ABC, CEP 09210-580, Santo André, Brasil
- Instituto de Química (IQ), Universidade Estadualde Campinas [GBM1], CEP 13083-970, Caixa Postal 6154, Campinas, SP, Brasil
| |
Collapse
|
717
|
Mignani S, Rodrigues J, Tomas H, Zablocka M, Shi X, Caminade AM, Majoral JP. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev 2018. [DOI: https:/doi.org/10.1039/c7cs00550d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
Overview of the use of dendrimers in combination with encapsulated and conjugated natural products and analogues as anti-cancer agents.
Collapse
Affiliation(s)
- Serge Mignani
- Université Paris Descartes, PRES Sorbonne Paris Cité, CNRS UMR 860, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique
- Paris
- France
- CQM – Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada
- Funchal
| | - João Rodrigues
- CQM – Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada
- Funchal
- Portugal
- School of Materials Science and Engineering/Center for Nano Energy Materials, Northwestern Polytechnical University
- Xi’an
| | - Helena Tomas
- CQM – Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada
- Funchal
- Portugal
| | - Maria Zablocka
- Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences
- 90-363 Lodz
- Poland
| | - Xiangyang Shi
- CQM – Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada
- Funchal
- Portugal
- State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University
- Shanghai 201620
| | - Anne-Marie Caminade
- Laboratoire de Chimie de Coordination du CNRS
- 31077 Toulouse Cedex 4
- France
- Université de Toulouse, UPS, INPT
- 31077 Toulouse Cedex
| | - Jean-Pierre Majoral
- Laboratoire de Chimie de Coordination du CNRS
- 31077 Toulouse Cedex 4
- France
- Université de Toulouse, UPS, INPT
- 31077 Toulouse Cedex
| |
Collapse
|
718
|
Abstract
Continued advancements in nanotechnology are expanding the boundaries of medical research, most notably as drug delivery agents for treatment against cancer. Drug delivery with nanotechnology can offer greater control over the biodistribution of therapeutic agents to improve the therapeutic index. In the last 20 years, a number of nanomedicines have transitioned into the clinic. As nanomedicines evolve, techniques to properly evaluate their safety and efficacy must also evolve. Characterization methods for nano-based materials must be adapted to the demands of nanomedicine developers and regulators. This second edition book provides updated characterization protocols designed to address the clinical potential of nanomedicines during their preclinical development. In this chapter, the characterization challenges of nanoparticles intended for drug delivery will be discussed, along with examples of advancements and improvements in nanomedicine characterization.
Collapse
|
719
|
Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer. JOURNAL OF DRUG DELIVERY 2017; 2017:9090325. [PMID: 29464123 PMCID: PMC5804325 DOI: 10.1155/2017/9090325] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 10/12/2017] [Accepted: 10/19/2017] [Indexed: 11/17/2022]
Abstract
In nanomedicine, targeted therapeutic nanoparticle (NP) is a virtual outcome of nanotechnology taking the advantage of cancer propagation pattern. Tying up all elements such as therapeutic or imaging agent, targeting ligand, and cross-linking agent with the NPs is the key concept to deliver the payload selectively where it intends to reach. The microenvironment of tumor tissues in lymphatic vessels can also help targeted NPs to achieve their anticipated accumulation depending on the formulation objectives. This review accumulates the application of poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) based NP systems, with a specific perspective in cancer. Nowadays, PLGA, PEG, or their combinations are the mostly used polymers to serve the purpose of targeted therapeutic NPs. Their unique physicochemical properties along with their biological activities are also discussed. Depending on the biological effects from parameters associated with existing NPs, several advantages and limitations have been explored in teaming up all the essential facts to give birth to targeted therapeutic NPs. Therefore, the current article will provide a comprehensive review of various approaches to fabricate a targeted system to achieve appropriate physicochemical properties. Based on such findings, researchers can realize the benefits and challenges for the next generation of delivery systems.
Collapse
|
720
|
Ebrahiminezhad A, Zare M, Kiyanpour S, Berenjian A, Niknezhad SV, Ghasemi Y. Biosynthesis of xanthangum‐coated INPs by using Xanthomonas campestris. IET Nanobiotechnol 2017; 12:254-258. [PMCID: PMC8676424 DOI: 10.1049/iet-nbt.2017.0199] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 10/26/2017] [Accepted: 11/04/2017] [Indexed: 11/25/2023] Open
Abstract
Synthesis of iron nanoparticles (INPs) with a biocompatible coating usually is a multistep process which requires harsh, special and protected reaction conditions. In the current experiment, the authors used Xanthomonas campestris cells to develop a facile method for fabrication of biocompatible INPs. Bacterial cells were supplied with ferric citrate as an iron precursor. Transmission electron microscopy micrographs exhibited that xanthan gum‐coated INPs are synthesised and deposited on the surface of X. campestris cells and produced nanoparticles were 20–80 nm in diameter with 41.7 nm mean particle size. Xanthan gum coating with about 7 nm thickness formed a clear hollow around each nanoparticle. According to thermogravimetric analysis, the coating was about 13.4% of the total INPs weight. Prepared particles had a zeta potential of −114 mv which is an ideal surface charge to make particles colloidally stable in aqueous matrixes. Xanthan gum‐coated INPs were non‐crystalline with low saturation magnetisation value of about 0.26 emu/g.
Collapse
Affiliation(s)
- Alireza Ebrahiminezhad
- Department of Medical BiotechnologySchool of Medicine, and Noncommunicable Diseases Research CentreFasa University of Medical SciencesFasaIran
- Department of Medical NanotechnologySchool of Advanced Medical Sciences and TechnologiesShiraz University of Medical SciencesShirazIran
- Department of Pharmaceutical BiotechnologySchool of Pharmacy and Pharmaceutical Sciences Research CentreShiraz University of Medical SciencesShirazIran
| | - Marziyeh Zare
- Department of Medical BiotechnologySchool of Medicine, and Noncommunicable Diseases Research CentreFasa University of Medical SciencesFasaIran
| | - Sedigheh Kiyanpour
- Department of Pharmaceutical BiotechnologySchool of Pharmacy and Pharmaceutical Sciences Research CentreShiraz University of Medical SciencesShirazIran
| | - Aydin Berenjian
- School of EngineeringFaculty of Science and EngineeringThe University of WaikatoHamiltonNew Zealand
| | - Seyyed Vahid Niknezhad
- Department of Pharmaceutical BiotechnologySchool of Pharmacy and Pharmaceutical Sciences Research CentreShiraz University of Medical SciencesShirazIran
| | - Younes Ghasemi
- Department of Medical NanotechnologySchool of Advanced Medical Sciences and TechnologiesShiraz University of Medical SciencesShirazIran
- Department of Pharmaceutical BiotechnologySchool of Pharmacy and Pharmaceutical Sciences Research CentreShiraz University of Medical SciencesShirazIran
| |
Collapse
|
721
|
Cassano D, Pocoví-Martínez S, Voliani V. Ultrasmall-in-Nano Approach: Enabling the Translation of Metal Nanomaterials to Clinics. Bioconjug Chem 2017; 29:4-16. [PMID: 29186662 DOI: 10.1021/acs.bioconjchem.7b00664] [Citation(s) in RCA: 73] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Currently, nanomaterials are of widespread use in daily commercial products. However, the most-promising and potentially impacting application is in the medical field. In particular, nanosized noble metals hold the promise of shifting the current medical paradigms for the detection and therapy of neoplasms thanks to the: (i) localized surface plasmon resonances (LSPRs), (ii) high electron density, and (iii) suitability for straightforward development of all-in-one nanoplatforms. Nonetheless, there is still no clinically approved noble metal nanomaterial for cancer therapy and diagnostics. The clinical translation of noble metal nanoparticles (NPs) is mainly prevented by the issue of persistence in organism after the medical action. Such persistence increases the likelihood of toxicity and the interference with common medical diagnoses. Size reduction to ultrasmall nanoparticles (USNPs) is a suitable approach to promoting metal excretion by the renal pathway. However, most of the functionalities of NPs are lost or severely altered in USNPs, jeopardizing clinical applications. A ground-breaking advance to jointly combine the appealing behaviors of NPs with metal excretion relies on the ultrasmall-in-nano approach for the design of all-in-one degradable nanoplatforms composed of USNPs. Such nanoarchitectures might lead to the delivery of a novel paradigm for nanotechnology, enabling the translation of noble metal nanomaterials to clinics to treat carcinomas in a less-invasive and more-efficient manner. This Review covers the recent progresses related to this exciting approach. The most-significant nanoarchitectures designed with the ultrasmall-in-nano approach are discussed, and perspectives on these nanoarchitectures are provided.
Collapse
Affiliation(s)
- Domenico Cassano
- Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia , Piazza San Silvestro 12-56126, Pisa, Italy.,NEST-Scuola Normale Superiore , Piazza San Silvestro 12-56126, Pisa, Italy
| | - Salvador Pocoví-Martínez
- National Research Council, Institute of Clinical Physiology , Via G. Moruzzi 1-56124, Pisa, Italy
| | - Valerio Voliani
- Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia , Piazza San Silvestro 12-56126, Pisa, Italy
| |
Collapse
|
722
|
Jonsson-Schmunk K, Schafer SC, Croyle MA. Impact of nanomedicine on hepatic cytochrome P450 3A4 activity: things to consider during pre-clinical and clinical studies. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2017. [DOI: 10.1007/s40005-017-0376-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
723
|
Zhu C, Xia Y. Biomimetics: reconstitution of low-density lipoprotein for targeted drug delivery and related theranostic applications. Chem Soc Rev 2017; 46:7668-7682. [PMID: 29104991 PMCID: PMC5725233 DOI: 10.1039/c7cs00492c] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Low-density lipoprotein (LDL), one of the four major groups of lipoproteins for lipid transport in vivo, is emerging as an attractive carrier for the targeted delivery of theranostic agents. In contrast to the synthetic systems, LDL particles are intrinsically biocompatible and biodegradable, together with reduced immunogenicity and natural capabilities to target cancerous cells and to escape from the recognition and elimination by the reticuloendothelial system. Enticed by these attributes, a number of strategies have been developed for reconstituting LDL particles, including conjugation to the apolipoprotein, insertion into the phospholipid layer, and loading into the core. Here we present a tutorial review on the development of reconstituted LDL (rLDL) particles for theranostic applications. We start with a brief introduction to LDL and LDL receptor, as well as the advantages of using rLDL particles as a natural and versatile platform for the targeted delivery of theranostic agents. After a discussion of commonly used strategies for the reconstitution of LDL, we highlight the applications of rLDL particles in the staging of disease progression, treatment of lesioned tissues, and delivery of photosensitizers for photodynamic cancer therapy. We finish this review with a perspective on the remaining challenges and future directions.
Collapse
Affiliation(s)
- Chunlei Zhu
- The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
| | | |
Collapse
|
724
|
Zhang Y, Wang XP, Perner S, Bankfalvi A, Schlücker S. Effect of Antigen Retrieval Methods on Nonspecific Binding of Antibody–Metal Nanoparticle Conjugates on Formalin-Fixed Paraffin-Embedded Tissue. Anal Chem 2017; 90:760-768. [DOI: 10.1021/acs.analchem.7b03144] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Yuying Zhang
- Physical Chemistry
I, Department of Chemistry and Center for Nanointegration
Duisburg-Essen (CENIDE), University of Duisburg-Essen, Universitätsstrasse 5, 45141 Essen, Germany
- Medical School of Nankai University, 94 Weijin Road, 300071 Tianjin, China
| | - Xin-Ping Wang
- Physical Chemistry
I, Department of Chemistry and Center for Nanointegration
Duisburg-Essen (CENIDE), University of Duisburg-Essen, Universitätsstrasse 5, 45141 Essen, Germany
| | - Sven Perner
- Pathology of the
University Medical Center Schleswig-Holstein, Campus Lübeck, Research Center Borstel−Leibniz Center for Medicine and Biosciences, Ratzeburger Allee 160, 23538 Lübeck, Germany
| | - Agnes Bankfalvi
- Institute
of Pathology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany
| | - Sebastian Schlücker
- Physical Chemistry
I, Department of Chemistry and Center for Nanointegration
Duisburg-Essen (CENIDE), University of Duisburg-Essen, Universitätsstrasse 5, 45141 Essen, Germany
| |
Collapse
|
725
|
Wang F, Porter M, Konstantopoulos A, Zhang P, Cui H. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. J Control Release 2017. [PMID: 28958854 DOI: 10.1016/jjc0nrel.2017.09.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/15/2023]
Abstract
Paclitaxel (PTX) is one of the most successful drugs ever used in cancer chemotherapy, acting against a variety of cancer types. Formulating PTX with Cremophor EL and ethanol (Taxol®) realized its clinical potential, but the formulation falls short of expectations due to side effects such as peripheral neuropathy, hypotension, and hypersensitivity. Abraxane®, the albumin bound PTX, represents a superior replacement of Taxol® that mitigates the side effects associated with Cremophor EL. While Abraxane® is now considered a gold standard in chemotherapy, its 21% response rate leaves much room for further improvement. The quest for safer and more effective cancer treatments has led to the development of a plethora of innovative PTX formulations, many of which are currently undergoing clinical trials. In this context, we review recent development of PTX drug delivery systems and analyze the design principles underpinning each delivery strategy. We chose several representative examples to highlight the opportunities and challenges of polymeric systems, lipid-based formulations, as well as prodrug strategies.
Collapse
Affiliation(s)
- Feihu Wang
- Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Michael Porter
- Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Alexandros Konstantopoulos
- Department of Biomedical Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Pengcheng Zhang
- Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Honggang Cui
- Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States; Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 North Broadway, Baltimore, MD 21231, United States; Institute for NanoBiotechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States.
| |
Collapse
|
726
|
Wang F, Porter M, Konstantopoulos A, Zhang P, Cui H. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. J Control Release 2017; 267:100-118. [PMID: 28958854 PMCID: PMC5723209 DOI: 10.1016/j.jconrel.2017.09.026] [Citation(s) in RCA: 101] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Revised: 09/12/2017] [Accepted: 09/18/2017] [Indexed: 12/28/2022]
Abstract
Paclitaxel (PTX) is one of the most successful drugs ever used in cancer chemotherapy, acting against a variety of cancer types. Formulating PTX with Cremophor EL and ethanol (Taxol®) realized its clinical potential, but the formulation falls short of expectations due to side effects such as peripheral neuropathy, hypotension, and hypersensitivity. Abraxane®, the albumin bound PTX, represents a superior replacement of Taxol® that mitigates the side effects associated with Cremophor EL. While Abraxane® is now considered a gold standard in chemotherapy, its 21% response rate leaves much room for further improvement. The quest for safer and more effective cancer treatments has led to the development of a plethora of innovative PTX formulations, many of which are currently undergoing clinical trials. In this context, we review recent development of PTX drug delivery systems and analyze the design principles underpinning each delivery strategy. We chose several representative examples to highlight the opportunities and challenges of polymeric systems, lipid-based formulations, as well as prodrug strategies.
Collapse
Affiliation(s)
- Feihu Wang
- Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Michael Porter
- Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Alexandros Konstantopoulos
- Department of Biomedical Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Pengcheng Zhang
- Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Honggang Cui
- Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States; Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 North Broadway, Baltimore, MD 21231, United States; Institute for NanoBiotechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States.
| |
Collapse
|
727
|
Anwar A, Siddiqui R, Hussain MA, Ahmed D, Shah MR, Khan NA. Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole. Parasitol Res 2017; 117:265-271. [PMID: 29218442 DOI: 10.1007/s00436-017-5701-x] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Accepted: 11/27/2017] [Indexed: 12/31/2022]
Abstract
Infectious diseases are the leading cause of morbidity and mortality, killing more than 15 million people worldwide. This is despite our advances in antimicrobial chemotherapy and supportive care. Nanoparticles offer a promising technology to enhance drug efficacy and formation of effective vehicles for drug delivery. Here, we conjugated amphotericin B, nystatin (macrocyclic polyenes), and fluconazole (azole) with silver nanoparticles. Silver-conjugated drugs were synthesized successfully and characterized by ultraviolet-visible spectrophotometry, Fourier transform infrared spectroscopy, and atomic force microscopy. Conjugated and unconjugated drugs were tested against Acanthamoeba castellanii belonging to the T4 genotype using amoebicidal assay and host cell cytotoxicity assay. Viability assays revealed that silver nanoparticles conjugated with amphotericin B (Amp-AgNPs) and nystatin (Nys-AgNPs) exhibited significant antiamoebic properties compared with drugs alone or AgNPs alone (P < 0.05) as determined by Trypan blue exclusion assay. In contrast, conjugation of fluconazole with AgNPs had limited effect on its antiamoebic properties. Notably, AgNP-coated drugs inhibited amoebae-mediated host cell cytotoxicity as determined by measuring lactate dehydrogenase release. Overall, here we present the development of a new formulation of more effective antiamoebic agents based on AgNPs coated with drugs that hold promise for future applications.
Collapse
Affiliation(s)
- Ayaz Anwar
- Department of Biological Sciences, School of Science and Technology, Sunway University, 47500, Subang Jaya, Selangor, Malaysia
| | - Ruqaiyyah Siddiqui
- Department of Biological Sciences, School of Science and Technology, Sunway University, 47500, Subang Jaya, Selangor, Malaysia
| | - Muhammad Asim Hussain
- International Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry, University of Karachi, Karachi, 75270, Pakistan
| | - Dania Ahmed
- International Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry, University of Karachi, Karachi, 75270, Pakistan
| | - Muhammad Raza Shah
- International Center for Chemical and Biological Sciences, H.E.J. Research Institute of Chemistry, University of Karachi, Karachi, 75270, Pakistan
| | - Naveed Ahmed Khan
- Department of Biological Sciences, School of Science and Technology, Sunway University, 47500, Subang Jaya, Selangor, Malaysia.
| |
Collapse
|
728
|
Kudarha RR, Sawant KK. Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2017; 81:607-626. [DOI: 10.1016/j.msec.2017.08.004] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Revised: 07/13/2017] [Accepted: 08/02/2017] [Indexed: 12/30/2022]
|
729
|
Dacoba TG, Olivera A, Torres D, Crecente-Campo J, Alonso MJ. Modulating the immune system through nanotechnology. Semin Immunol 2017; 34:78-102. [PMID: 29032891 PMCID: PMC5774666 DOI: 10.1016/j.smim.2017.09.007] [Citation(s) in RCA: 72] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 09/18/2017] [Accepted: 09/18/2017] [Indexed: 12/11/2022]
Abstract
Nowadays, nanotechnology-based modulation of the immune system is presented as a cutting-edge strategy, which may lead to significant improvements in the treatment of severe diseases. In particular, efforts have been focused on the development of nanotechnology-based vaccines, which could be used for immunization or generation of tolerance. In this review, we highlight how different immune responses can be elicited by tuning nanosystems properties. In addition, we discuss specific formulation approaches designed for the development of anti-infectious and anti-autoimmune vaccines, as well as those intended to prevent the formation of antibodies against biologicals.
Collapse
Affiliation(s)
- Tamara G Dacoba
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Ana Olivera
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Dolores Torres
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - José Crecente-Campo
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain.
| | - María José Alonso
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain.
| |
Collapse
|
730
|
Nanomedicine, an emerging therapeutic strategy for oral cancer therapy. Oral Oncol 2017; 76:1-7. [PMID: 29290280 DOI: 10.1016/j.oraloncology.2017.11.014] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2017] [Revised: 11/06/2017] [Accepted: 11/12/2017] [Indexed: 01/12/2023]
Abstract
Oral cavity and oropharyngeal carcinomas (oral cancer) represents a significant cause of morbidity and mortality. Despite efforts in improving early diagnosis and treatment, the 5-year survival rate of advanced stage of the disease is less than 63%. The field of nanomedicine has offered promising diagnostic and therapeutic advances in cancer. Indeed, several platforms have been clinically approved for cancer therapy, while other promising systems are undergoing exploration in clinical trials. With its ability to deliver drugs, nucleic acids, and MRI contrast agents with high efficiency, nanomedicine platforms offer the potential to improve drug efficacy and tolerability. The aim of the present mini-review is to summarize the current preclinical status of nanotechnology systems for oral cancer therapy. The nanoplatforms for delivery of chemopreventive agents presented herein resulted in significantly higher anti-tumor activity than free forms of the drug, even against a chemo-resistant cell line. Impressive results have also been obtained using nanoparticles to deliver chemotherapeutics, resulting in reduced toxicity both in vitro and in vivo. Nanoparticles have also led to improvements in efficacy of photodynamic therapies through the development of targeted magnetic nanoparticles. Finally, gene therapy using nanoparticles demonstrated promising results specifically with regards to inhibition of gene expression. Of the few in vivo studies that have been reported, many of these used animal models with several limitations, which will be discussed herein. Lastly, we will discuss several future perspectives in oral cancer nanoparticle-based therapy and the development of appropriate animal models, distinguishing between oral cavity and oropharyngeal carcinoma.
Collapse
|
731
|
Roacho-Perez JA, Gallardo-Blanco HL, Sanchez-Dominguez M, Garcia-Casillas PE, Chapa-Gonzalez C, Sanchez-Dominguez CN. Nanoparticles for death‑induced gene therapy in cancer (Review). Mol Med Rep 2017; 17:1413-1420. [PMID: 29257213 DOI: 10.3892/mmr.2017.8091] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2017] [Accepted: 09/05/2017] [Indexed: 11/05/2022] Open
Abstract
Due to the high toxicity and side effects of the use of traditional chemotherapy in cancer, scientists are working on the development of alternative therapeutic technologies. An example of this is the use of death‑induced gene therapy. This therapy consists of the killing of tumor cells via transfection with plasmid DNA (pDNA) that contains a gene which produces a protein that results in the apoptosis of cancerous cells. The cell death is caused by the direct activation of apoptosis (apoptosis‑induced gene therapy) or by the protein toxic effects (toxin‑induced gene therapy). The introduction of pDNA into the tumor cells has been a challenge for the development of this therapy. The most recent implementation of gene vectors is the use of polymeric or inorganic nanoparticles, which have biological and physicochemical properties (shape, size, surface charge, water interaction and biodegradation rate) that allow them to carry the pDNA into the tumor cell. Furthermore, nanoparticles may be functionalized with specific molecules for the recognition of molecular markers on the surface of tumor cells. The binding between the nanoparticle and the tumor cell induces specific endocytosis, avoiding toxicity in healthy cells. Currently, there are no clinical protocols approved for the use of nanoparticles in death‑induced gene therapy. There are still various challenges in the design of the perfect transfection vector, however nanoparticles have been demonstrated to be a suitable candidate. This review describes the role of nanoparticles used for pDNA transfection and key aspects for their use in death‑induced gene therapy.
Collapse
Affiliation(s)
- Jorge A Roacho-Perez
- Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 64460, Mexico
| | - Hugo L Gallardo-Blanco
- Department of Genetics, Faculty of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 64460, Mexico
| | - Margarita Sanchez-Dominguez
- Centro de Investigacion en Materiales Avanzados, S. C. (CIMAV, S.C.), Unidad Monterrey, Apodaca, Nuevo Leon 66628, Mexico
| | - Perla E Garcia-Casillas
- Universidad Autonoma de Ciudad Juarez, Institute of Engineering and Technology, Ciudad Juarez, Chihuahua 32310, Mexico
| | - Christian Chapa-Gonzalez
- Universidad Autonoma de Ciudad Juarez, Institute of Engineering and Technology, Ciudad Juarez, Chihuahua 32310, Mexico
| | - Celia N Sanchez-Dominguez
- Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 64460, Mexico
| |
Collapse
|
732
|
Andreu V, Arruebo M. Current progress and challenges of nanoparticle-based therapeutics in pain management. J Control Release 2017; 269:189-213. [PMID: 29146243 DOI: 10.1016/j.jconrel.2017.11.018] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 11/10/2017] [Accepted: 11/11/2017] [Indexed: 02/07/2023]
Abstract
Pain is a widespread and growing health problem worldwide that exerts a considerable social and economic impact on both patients and healthcare systems and, therefore, on society in general. Although current treatment modalities include a wide variety of pharmacological and non-pharmacological approaches, due to the complexity of pain and individual differences in clinical response these options are not always effective in mitigating and relieving pain. In addition, some pain drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics and opioids show several unfavorable side effects. Therefore, current research advances in this medical field are based on the development of potential treatments to address many of the unmet needs and to overcome the existing limitations in pain management. Nanoparticle drug delivery systems present an exciting opportunity as alternative platforms to improve efficacy and safety of medications currently in use. Herein, we review a broad range of nanoparticle formulations (organic nanostructures and inorganic nanoparticles), which have been developed to encapsulate an array of painkillers, paying special attention to the key advantages that these systems offer, (compared to the use of the free drug), as well as to the more relevant results of preclinical studies in animal models. Additionally, we will briefly discuss the impact of some of these nanoformulations in clinical trials.
Collapse
Affiliation(s)
- Vanesa Andreu
- Department of Chemical Engineering, Aragon Institute of Nanoscience (INA), University of Zaragoza, Campus Río Ebro-Edificio I+D, C/Poeta Mariano Esquillor S/N, 50018 Zaragoza, Spain; Aragon Health Research Institute (IIS), Aragón, 50009 Zaragoza, Spain.
| | - Manuel Arruebo
- Department of Chemical Engineering, Aragon Institute of Nanoscience (INA), University of Zaragoza, Campus Río Ebro-Edificio I+D, C/Poeta Mariano Esquillor S/N, 50018 Zaragoza, Spain; Aragon Health Research Institute (IIS), Aragón, 50009 Zaragoza, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, 28029 Madrid, Spain
| |
Collapse
|
733
|
Gomes CP, Lopes CDF, Leitner M, Ebner A, Hinterdorfer P, Pêgo AP. Atomic Force Microscopy as a Tool to Assess the Specificity of Targeted Nanoparticles in Biological Models of High Complexity. Adv Healthc Mater 2017; 6. [PMID: 28752592 DOI: 10.1002/adhm.201700597] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 06/19/2017] [Indexed: 12/28/2022]
Abstract
The ability to design nanoparticle delivery systems capable of selectively target their payloads to specific cell populations is still a major caveat in nanomedicine. One of the main hurdles is the fact that each nanoparticle formulation needs to be precisely tuned to match the specificities of the target cell and route of administration. In this work, molecular recognition force spectroscopy (MRFS) is presented as a tool to evaluate the specificity of neuron-targeted trimethyl chitosan nanoparticles to neuronal cell populations in biological samples of different complexity. The use of atomic force microscopy tips functionalized with targeted or non-targeted nanoparticles made it possible to assess the specific interaction of each formulation with determined cell surface receptors in a precise fashion. More importantly, the combination of MRFS with fluorescent microscopy allowed to probe the nanoparticles vectoring capacity in models of high complexity, such as primary mixed cultures, as well as specific subcellular regions in histological tissues. Overall, this work contributes for the establishment of MRFS as a powerful alternative technique to animal testing in vector design and opens new avenues for the development of advanced targeted nanomedicines.
Collapse
Affiliation(s)
- Carla P. Gomes
- INEB – Instituto de Engenharia Biomédica i3S – Instituto de Investigação e Inovação em Saúde Rua Alfredo Allen 208 4200‐135 Porto Portugal
- Faculdade de Engenharia da Universidade do Porto R. Dr. Roberto Frias 4200‐465 Porto Portugal
| | - Cátia D. F. Lopes
- INEB – Instituto de Engenharia Biomédica i3S – Instituto de Investigação e Inovação em Saúde Rua Alfredo Allen 208 4200‐135 Porto Portugal
- Faculdade de Medicina da Universidade do Porto Alameda Prof. Hernâni Monteiro 4200‐319 Porto Portugal
| | - Michael Leitner
- Institute of Biophysics Johannes Kepler University Gruberstraße 40 4020 Linz Austria
| | - Andreas Ebner
- Institute of Biophysics Johannes Kepler University Gruberstraße 40 4020 Linz Austria
| | - Peter Hinterdorfer
- Institute of Biophysics Johannes Kepler University Gruberstraße 40 4020 Linz Austria
| | - Ana P. Pêgo
- INEB – Instituto de Engenharia Biomédica i3S – Instituto de Investigação e Inovação em Saúde Rua Alfredo Allen 208 4200‐135 Porto Portugal
- Faculdade de Engenharia da Universidade do Porto R. Dr. Roberto Frias 4200‐465 Porto Portugal
- ICBAS – Instituto de Ciências Biomédicas Abel Salazar Universidade do Porto Rua de Jorge Viterbo Ferreira 228 4050‐313 Porto Portugal
| |
Collapse
|
734
|
Lewinski NA, Jimenez I, McInnes BT. An annotated corpus with nanomedicine and pharmacokinetic parameters. Int J Nanomedicine 2017; 12:7519-7527. [PMID: 29066897 PMCID: PMC5644562 DOI: 10.2147/ijn.s137117] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
A vast amount of data on nanomedicines is being generated and published, and natural language processing (NLP) approaches can automate the extraction of unstructured text-based data. Annotated corpora are a key resource for NLP and information extraction methods which employ machine learning. Although corpora are available for pharmaceuticals, resources for nanomedicines and nanotechnology are still limited. To foster nanotechnology text mining (NanoNLP) efforts, we have constructed a corpus of annotated drug product inserts taken from the US Food and Drug Administration's Drugs@FDA online database. In this work, we present the development of the Engineered Nanomedicine Database corpus to support the evaluation of nanomedicine entity extraction. The data were manually annotated for 21 entity mentions consisting of nanomedicine physicochemical characterization, exposure, and biologic response information of 41 Food and Drug Administration-approved nanomedicines. We evaluate the reliability of the manual annotations and demonstrate the use of the corpus by evaluating two state-of-the-art named entity extraction systems, OpenNLP and Stanford NER. The annotated corpus is available open source and, based on these results, guidelines and suggestions for future development of additional nanomedicine corpora are provided.
Collapse
Affiliation(s)
- Nastassja A Lewinski
- Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA
| | - Ivan Jimenez
- Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA
| | - Bridget T McInnes
- Department of Computer Science, Virginia Commonwealth University, Richmond, VA, USA
| |
Collapse
|
735
|
Challenges and opportunities in developing targeted molecular imaging to determine inner ear defects of sensorineural hearing loss. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2017; 14:397-404. [PMID: 29074310 DOI: 10.1016/j.nano.2017.10.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Revised: 10/05/2017] [Accepted: 10/13/2017] [Indexed: 12/30/2022]
Abstract
The development of inner ear gene carriers and delivery systems has enabled genetic defects to be repaired and hearing to be restored in mouse models. Today, promising advances in translational therapies provide confidence that targeted molecular therapy for inner ear diseases will be developed. Unfortunately, the currently available non-invasive modalities, such as Computerized Tomography scan or Magnetic Resonance Imaging provide insufficient resolution to identify most pathologies of the human inner ear, even when the current generation of contrast agents is utilized. The development of targeted contrast agents may play a critical role in determining the cause of, and treatment for, sensorineural hearing loss. Such agents should be able to pass through the cochlea barriers, possess minimal cytotoxicity, and easily conjugate to a targeting agent, without distorting the anatomic details. This review focuses on a series of contrast agents which may fit these criteria for potential clinical application.
Collapse
|
736
|
Florek J, Caillard R, Kleitz F. Evaluation of mesoporous silica nanoparticles for oral drug delivery - current status and perspective of MSNs drug carriers. NANOSCALE 2017; 9:15252-15277. [PMID: 28984885 DOI: 10.1039/c7nr05762h] [Citation(s) in RCA: 124] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
The oral pathway is considered as the most common method for drug administration, although many drugs, especially the highly pH- and/or enzymatic biodegradable peptide drugs, are very difficult to formulate and achieve a good intestinal absorption. Efficient systematic absorption of an active substance, delivered via oral ingestion, is only achievable if the drug (1) is substantially present as a solution in the gastrointestinal tract, (2) is able to penetrate through the intestinal mucus, (3) overcomes the different gastrointestinal barriers, and (4) provides an effective therapeutic dose. Therefore, optimization of oral bioavailability of poorly-soluble drugs still remains a significant challenge for the pharmaceutical industry. Even though numerous conventional drug carriers have successfully solved some of the issues related to oral delivery of poorly-soluble drugs, only few of them met commercialization requirements. These drawbacks have led the scientific world to reconsider its approaches toward targeted drug delivery systems and researchers started looking for alternative vectorized carriers. In this area, nanoparticle-based materials have several significant advantages over free and non-formulated drugs. For example, nanosized porous silica carriers allow for more sustained and controlled drug release or improved oral bioavailability. Thus, in the present review, we will highlight the most important features of nanostructured silica drug carriers, such as particle size, particle shape, surface roughness or surface functionalization, and underline the key advantages of these nanosupports. In particular, this article will discuss recent progress and challenges in the area of mesoporous silica nanocarriers used for oral drug delivery. Additional emphasis will be set on the biological and chemical features of the gastrointestinal tract as well as currently tested nanoformulations and strategies to avoid drug degradation in the gastrointestinal environment.
Collapse
Affiliation(s)
- Justyna Florek
- Department of Inorganic Chemistry - Functional Materials, Faculty of Chemistry, University of Vienna, Währinger Str. 42, 1090 Vienna, Austria.
| | | | | |
Collapse
|
737
|
Kumar A, Tan A, Wong J, Spagnoli JC, Lam J, Blevins BD, G N, Thorne L, Ashkan K, Xie J, Liu H. Nanotechnology for Neuroscience: Promising Approaches for Diagnostics, Therapeutics and Brain Activity Mapping. ADVANCED FUNCTIONAL MATERIALS 2017; 27:1700489. [PMID: 30853878 PMCID: PMC6404766 DOI: 10.1002/adfm.201700489] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Unlocking the secrets of the brain is a task fraught with complexity and challenge - not least due to the intricacy of the circuits involved. With advancements in the scale and precision of scientific technologies, we are increasingly equipped to explore how these components interact to produce a vast range of outputs that constitute function and disease. Here, an insight is offered into key areas in which the marriage of neuroscience and nanotechnology has revolutionized the industry. The evolution of ever more sophisticated nanomaterials culminates in network-operant functionalized agents. In turn, these materials contribute to novel diagnostic and therapeutic strategies, including drug delivery, neuroprotection, neural regeneration, neuroimaging and neurosurgery. Further, the entrance of nanotechnology into future research arenas including optogenetics, molecular/ion sensing and monitoring, and piezoelectric effects is discussed. Finally, considerations in nanoneurotoxicity, the main barrier to clinical translation, are reviewed, and direction for future perspectives is provided.
Collapse
Affiliation(s)
- Anil Kumar
- State Key Laboratory of Crystal Materials, Shandong University, Jinan 250100, China
| | - Aaron Tan
- UCL Medical School, University College London (UCL), London, United Kingdom
| | - Joanna Wong
- Imperial College School of Medicine, Imperial College London,London, United Kingdom
| | - Jonathan Clayton Spagnoli
- Department of Chemistry, Bio-Imaging Research Center, University of Georgia, Athens, Georgia 30602, United States
| | - James Lam
- UCL Medical School, University College London (UCL), London, United Kingdom
| | - Brianna Diane Blevins
- Department of Chemistry, Bio-Imaging Research Center, University of Georgia, Athens, Georgia 30602, United States
| | - Natasha G
- UCL Medical School, University College London (UCL), London, United Kingdom
| | - Lewis Thorne
- Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom
| | - Keyoumars Ashkan
- Department of Neurosurgery, King's College Hospital NHS Foundation Trust, King's College London, London, United Kingdom
| | - Jin Xie
- Department of Chemistry, Bio-Imaging Research Center, University of Georgia, Athens, Georgia 30602, United States
| | - Hong Liu
- State Key Laboratory of Crystal Materials, Shandong University, Jinan 250100, China
| |
Collapse
|
738
|
Khoshnevisan K, Daneshpour M, Barkhi M, Gholami M, Samadian H, Maleki H. The promising potentials of capped gold nanoparticles for drug delivery systems. J Drug Target 2017; 26:525-532. [PMID: 28972797 DOI: 10.1080/1061186x.2017.1387790] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Fabrication and characterisation of gold nanoparticles (GNPs) through reducing agents and different capped agents are one of their most attractive applications in biomedicine. GNPs are coated using various agents such as carbohydrate, amino acids, peptides and proteins. These capped gold nanoparticles (C-GNPs) are applied for wide different applications including drug delivery in the recent decade and potential treatment and diagnosis in drug delivery systems (DDS). Recent studies have shown that these novel compounds and conjugated-nanoparticles drugs play a key role for the promising cure of high-risk refractory diseases. In addition, it seems that these compounds have a capability for potential treatment of certain cancers. In this review, a well-defined description of C-GNPs and the application of these nanoparticles are discussed. Our study revealed that C-GNPs with anticancer drugs or new compounds could be potentially applied for biomedical usage especially in cancer therapy.
Collapse
Affiliation(s)
- Kamyar Khoshnevisan
- a Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute , Tehran University of Medical Sciences , Tehran , Iran.,b Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute , Tehran University of Medical Sciences , Tehran , Iran
| | - Maryam Daneshpour
- c Department of Biotechnology, School of Advanced Technologies in Medicine , Shahid Beheshti University of Medical Sciences , Tehran , Iran
| | - Mohammad Barkhi
- d University of Applied Science and Technology (UAST), Zar Center , Karaj , Iran
| | - Morteza Gholami
- b Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute , Tehran University of Medical Sciences , Tehran , Iran.,e Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute , Tehran University of Medical Sciences , Tehran , Iran
| | - Hadi Samadian
- f Department of Medical Nanotechnology, School of Advanced Technologies in Medicine , Tehran University of Medical Sciences , Tehran , Iran
| | - Hassan Maleki
- f Department of Medical Nanotechnology, School of Advanced Technologies in Medicine , Tehran University of Medical Sciences , Tehran , Iran
| |
Collapse
|
739
|
Franco MS, Oliveira MC. Ratiometric drug delivery using non-liposomal nanocarriers as an approach to increase efficacy and safety of combination chemotherapy. Biomed Pharmacother 2017; 96:584-595. [PMID: 29035823 DOI: 10.1016/j.biopha.2017.10.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 09/27/2017] [Accepted: 10/02/2017] [Indexed: 10/18/2022] Open
Abstract
The observation that different drug ratios of the same drug combination can lead to synergistic or antagonistic effects when tested against the same cancer cell line in vitro gave rise to a new trend, the ratiometric delivery. This strategy consists of co-encapsulating a specific synergistic ratio of a drug combination into a nanocarrier so that synergism observed in vitro will be faithfully translated to in vivo, optimizing combination therapy. In this review we focus on how to quantify synergism in vitro, followed by how this affected the evolution of nanocarriers culminating in the ratiometric delivery, and finally we summarize the results of the non-liposomal formulations that were built upon this concept.
Collapse
Affiliation(s)
- Marina Santiago Franco
- Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
| | - Mônica Cristina Oliveira
- Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, 31270-901, Belo Horizonte, Minas Gerais, Brazil.
| |
Collapse
|
740
|
Personalized Nanomedicine: A Revolution at the Nanoscale. J Pers Med 2017; 7:jpm7040012. [PMID: 29023366 PMCID: PMC5748624 DOI: 10.3390/jpm7040012] [Citation(s) in RCA: 76] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Revised: 10/04/2017] [Accepted: 10/04/2017] [Indexed: 12/24/2022] Open
Abstract
Nanomedicine is an interdisciplinary research field that results from the application of nanotechnology to medicine and has the potential to significantly improve some current treatments. Specifically, in the field of personalized medicine, it is expected to have a great impact in the near future due to its multiple advantages, namely its versatility to adapt a drug to a cohort of patients. In the present review, the properties and requirements of pharmaceutical dosage forms at the nanoscale, so-called nanomedicines, are been highlighted. An overview of the main current nanomedicines in pre-clinical and clinical development is presented, detailing the challenges to the personalization of these therapies. Next, the process of development of novel nanomedicines is described, from their design in research labs to their arrival on the market, including considerations for the design of nanomedicines adapted to the requirements of the market to achieve safe, effective, and quality products. Finally, attention is given to the point of view of the pharmaceutical industry, including regulation issues applied to the specific case of personalized medicine. The authors expect this review to be a useful overview of the current state of the art of nanomedicine research and industrial production, and the future opportunities of personalized medicine in the upcoming years. The authors encourage the development and marketing of novel personalized nanomedicines.
Collapse
|
741
|
Chen F, Ma K, Zhang L, Madajewski B, Zanzonico P, Sequeira S, Gonen M, Wiesner U, Bradbury MS. Target-or-Clear Zirconium-89 Labeled Silica Nanoparticles for Enhanced Cancer-Directed Uptake in Melanoma: A Comparison of Radiolabeling Strategies. CHEMISTRY OF MATERIALS : A PUBLICATION OF THE AMERICAN CHEMICAL SOCIETY 2017; 29:8269-8281. [PMID: 29123332 PMCID: PMC5675572 DOI: 10.1021/acs.chemmater.7b02567] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Designing a nanomaterials platform with high target-to-background ratios has long been one of the major challenges in the field of nanomedicine. Here, we introduce a "target-or-clear" multifunctional nanoparticle platform that demonstrates high tumor-targeting efficiency and retention while minimizing off-target effects. Encouraged by the favorable preclinical and clinical pharmacokinetic profiles derived after fine-tuning surface chemical properties of radioiodinated (124I, t1/2 = 100.2 h) ultrasmall cRGDY-conjugated fluorescent silica nanoparticles (C dots), we sought to investigate how the biological properties of these radioconjugates could be influenced by the conjugation of radiometals such as zirconium-89 (89Zr, t1/2 = 78.4 h) using two different strategies: chelator-free and chelator-based radiolabeling. The attachment of 89Zr to newer, surface-aminated, integrin-targeting C' dots using a two-pot synthesis approach led to favorable pharmacokinetics and clearance profiles as well as high tumor uptake and target-to-background ratios in human melanoma models relative to biological controls while maintaining particle sizes below the effective renal glomerular filtration size cutoff <10 nm. Nanoconjugates were also characterized in terms of their radiostability and plasma residence half-lives. Our 89Zr-labeled ultrasmall hybrid organic-inorganic particle is a clinically promising positron emission tomography tracer offering radiobiological properties suitable for enhanced molecularly targeted cancer imaging applications.
Collapse
Affiliation(s)
- Feng Chen
- Department of Radiology, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
| | - Kai Ma
- Department of Materials Science & Engineering, Cornell University, Ithaca, New York 14853, United States
| | - Li Zhang
- Department of Radiology, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
| | - Brian Madajewski
- Department of Radiology, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
| | - Pat Zanzonico
- Department of Medical Physics, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
| | - Sonia Sequeira
- Research and Technology Management, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
| | - Mithat Gonen
- Department of Epidemiology and Biostatistics, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
| | - Ulrich Wiesner
- Department of Materials Science & Engineering, Cornell University, Ithaca, New York 14853, United States
| | - Michelle S. Bradbury
- Department of Radiology, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
- Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, New York, New York 10065, United States
| |
Collapse
|
742
|
Fan J, Wang S, Sun W, Guo S, Kang Y, Du J, Peng X. Anticancer drug delivery systems based on inorganic nanocarriers with fluorescent tracers. AIChE J 2017. [DOI: 10.1002/aic.15976] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Jiangli Fan
- State Key Laboratory of Fine Chemicals; Dalian University of Technology; Dalian 116024 China
| | - Suzhen Wang
- State Key Laboratory of Fine Chemicals; Dalian University of Technology; Dalian 116024 China
| | - Wen Sun
- State Key Laboratory of Fine Chemicals; Dalian University of Technology; Dalian 116024 China
| | - Shigang Guo
- State Key Laboratory of Fine Chemicals; Dalian University of Technology; Dalian 116024 China
| | - Yao Kang
- State Key Laboratory of Fine Chemicals; Dalian University of Technology; Dalian 116024 China
| | - Jianjun Du
- State Key Laboratory of Fine Chemicals; Dalian University of Technology; Dalian 116024 China
| | - Xiaojun Peng
- State Key Laboratory of Fine Chemicals; Dalian University of Technology; Dalian 116024 China
| |
Collapse
|
743
|
Duro-Castano A, Nebot VJ, Niño-Pariente A, Armiñán A, Arroyo-Crespo JJ, Paul A, Feiner-Gracia N, Albertazzi L, Vicent MJ. Capturing "Extraordinary" Soft-Assembled Charge-Like Polypeptides as a Strategy for Nanocarrier Design. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2017; 29:1702888. [PMID: 28834624 DOI: 10.1002/adma.201702888] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 07/03/2017] [Indexed: 05/24/2023]
Abstract
The rational design of nanomedicines is a challenging task given the complex architectures required for the construction of nanosized carriers with embedded therapeutic properties and the complex interface of these materials with the biological environment. Herein, an unexpected charge-like attraction mechanism of self-assembly for star-shaped polyglutamates in nonsalty aqueous solutions is identified, which matches the ubiquitous "ordinary-extraordinary" phenomenon previously described by physicists. For the first time, a bottom-up methodology for the stabilization of these nanosized soft-assembled star-shaped polyglutamates is also described, enabling the translation of theoretical research into nanomaterials with applicability within the drug-delivery field. Covalent capture of these labile assemblies provides access to unprecedented architectures to be used as nanocarriers. The enhanced in vitro and in vivo properties of these novel nanoconstructs as drug-delivery systems highlight the potential of this approach for tumor-localized as well as lymphotropic delivery.
Collapse
Affiliation(s)
- Aroa Duro-Castano
- Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Av Eduardo Primo Yúfera 3, 46012, Valencia, Spain
| | - Vicent J Nebot
- Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Av Eduardo Primo Yúfera 3, 46012, Valencia, Spain
| | - Amaya Niño-Pariente
- Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Av Eduardo Primo Yúfera 3, 46012, Valencia, Spain
| | - Ana Armiñán
- Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Av Eduardo Primo Yúfera 3, 46012, Valencia, Spain
| | - Juan J Arroyo-Crespo
- Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Av Eduardo Primo Yúfera 3, 46012, Valencia, Spain
| | - Alison Paul
- School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff, CF10 3AT, UK
| | - Natalia Feiner-Gracia
- Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Carrer de Baldiri Reixac 15-21, 08028, Barcelona, Spain
| | - Lorenzo Albertazzi
- Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Carrer de Baldiri Reixac 15-21, 08028, Barcelona, Spain
| | - María J Vicent
- Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Av Eduardo Primo Yúfera 3, 46012, Valencia, Spain
| |
Collapse
|
744
|
Mehra NK, Jain AK, Nahar M. Carbon nanomaterials in oncology: an expanding horizon. Drug Discov Today 2017; 23:1016-1025. [PMID: 28965869 DOI: 10.1016/j.drudis.2017.09.013] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 08/28/2017] [Accepted: 09/18/2017] [Indexed: 12/20/2022]
Abstract
Carbon nanomaterials have been attracting attention in oncology for the development of safe and effective cancer nanomedicines in increasing improved patient compliance for generally recognized as safe (GRAS) prominence. Toxicity, safety and efficacy of carbon nanomaterials are the major concerns in cancer theranostics. Various parameters such as particle size and shape or surface morphology, surface charge, composition, oxidation and nonoxidative-stress-related mechanisms are prone to toxicity of the carbon nanomaterials. Currently, few cancer-related products have been available on the market, although some are underway in preclinical and clinical phases. Thus, our main aim is to provide comprehensive details on the carbon nanomaterials in oncology from the past two decades for patient compliance and safety.
Collapse
Affiliation(s)
- Neelesh K Mehra
- Sentiss Research Centre, Sentiss Pharma, Gurgaon, Haryana 122001, India.
| | - Amit K Jain
- Department of Chemical Engineering, Texas Tech University, Lubbock, TX 79409, USA.
| | - Manoj Nahar
- Sentiss Research Centre, Sentiss Pharma, Gurgaon, Haryana 122001, India
| |
Collapse
|
745
|
Browning RJ, Reardon PJT, Parhizkar M, Pedley RB, Edirisinghe M, Knowles JC, Stride E. Drug Delivery Strategies for Platinum-Based Chemotherapy. ACS NANO 2017; 11:8560-8578. [PMID: 28829568 DOI: 10.1021/acsnano.7b04092] [Citation(s) in RCA: 143] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Few chemotherapeutics have had such an impact on cancer management as cis-diamminedichloridoplatinum(II) (CDDP), also known as cisplatin. The first member of the platinum-based drug family, CDDP's potent toxicity in disrupting DNA replication has led to its widespread use in multidrug therapies, with particular benefit in patients with testicular cancers. However, CDDP also produces significant side effects that limit the maximum systemic dose. Various strategies have been developed to address this challenge including encapsulation within micro- or nanocarriers and the use of external stimuli such as ultrasound to promote uptake and release. The aim of this review is to look at these strategies and recent scientific and clinical developments.
Collapse
Affiliation(s)
- Richard J Browning
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford , Oxford OX1 2JD, United Kingdom
| | | | | | | | | | - Jonathan C Knowles
- Department of Nanobiomedical Science and BK21 Plus NBM, Global Research Center for Regenerative Medicine, Dankook University , 518-10 Anseo-dong, Dongnam-gu, Cheonan, Chungcheongnam-do, Republic of Korea
- The Discoveries Centre for Regenerative and Precision Medicine, UCL Campus , Gower Street, London WC1E 6BT, United Kingdom
| | - Eleanor Stride
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford , Oxford OX1 2JD, United Kingdom
| |
Collapse
|
746
|
Rajchakit U, Sarojini V. Recent Developments in Antimicrobial-Peptide-Conjugated Gold Nanoparticles. Bioconjug Chem 2017; 28:2673-2686. [DOI: 10.1021/acs.bioconjchem.7b00368] [Citation(s) in RCA: 103] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Urawadee Rajchakit
- School of Chemical Sciences, The University of Auckland, Private Bag, 92019 Auckland, New Zealand
| | - Vijayalekshmi Sarojini
- School of Chemical Sciences, The University of Auckland, Private Bag, 92019 Auckland, New Zealand
| |
Collapse
|
747
|
Groult H, Poupard N, Herranz F, Conforto E, Bridiau N, Sannier F, Bordenave S, Piot JM, Ruiz-Cabello J, Fruitier-Arnaudin I, Maugard T. Family of Bioactive Heparin-Coated Iron Oxide Nanoparticles with Positive Contrast in Magnetic Resonance Imaging for Specific Biomedical Applications. Biomacromolecules 2017; 18:3156-3167. [PMID: 28850787 DOI: 10.1021/acs.biomac.7b00797] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH) are well-known for their anticoagulant properties. There is also currently a growing interest in using LMWH in targeted cancer therapy. In particular, several types inhibit heparanase, a key enzyme overexpressed in the tumor microenvironment that promotes angiogenesis progression and metastasis spreading. Here, we propose iron oxide nanoparticles (HEP-IONP) coated with different heparins of distinct anticoagulant/anti-heparanase activity ratios and suitable for positive contrast in magnetic resonance imaging. As a proof of concept, magnetic resonance angiography (MRA) was conducted in mice up to 3 h after intravenous administration. This new IONP-based positive contrast appropriate for clinic together with the long vascular circulating times can enable innovative theranostic applications if combined with the various bioactivities of the heparins. Indeed, we showed, using advanced in vitro tests, how HEP-IONP anticoagulant or anti-heparanase activities were maintained depending on the heparin species used for the coating. Overall, the study allowed presenting an IONP coated with a commercial LMWH (Lovenox) suggested as a theranostic translational probe for MRA diagnostic and treatment of thrombosis, and an antitumor IONP coated with a specific depolymerized heparin to be used in targeted therapy and diagnostic modalities.
Collapse
Affiliation(s)
- Hugo Groult
- UMR CNRS 7266 LIENSs, Approches Moléculaires Environnement-Santé environnement (AMES), University of La Rochelle , La Rochelle, France
| | - Nicolas Poupard
- UMR CNRS 7266 LIENSs, Approches Moléculaires Environnement-Santé environnement (AMES), University of La Rochelle , La Rochelle, France
| | - Fernando Herranz
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) , Madrid, Spain
| | - Egle Conforto
- UMR CNRS 7356 LaSIE, University of La Rochelle , La Rochelle, France
| | - Nicolas Bridiau
- UMR CNRS 7266 LIENSs, Approches Moléculaires Environnement-Santé environnement (AMES), University of La Rochelle , La Rochelle, France
| | - Fréderic Sannier
- UMR CNRS 7266 LIENSs, Approches Moléculaires Environnement-Santé environnement (AMES), University of La Rochelle , La Rochelle, France
| | - Stéphanie Bordenave
- UMR CNRS 7266 LIENSs, Approches Moléculaires Environnement-Santé environnement (AMES), University of La Rochelle , La Rochelle, France
| | - Jean-Marie Piot
- UMR CNRS 7266 LIENSs, Approches Moléculaires Environnement-Santé environnement (AMES), University of La Rochelle , La Rochelle, France
| | - Jesús Ruiz-Cabello
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) , Madrid, Spain
| | - Ingrid Fruitier-Arnaudin
- UMR CNRS 7266 LIENSs, Approches Moléculaires Environnement-Santé environnement (AMES), University of La Rochelle , La Rochelle, France
| | - Thierry Maugard
- UMR CNRS 7266 LIENSs, Approches Moléculaires Environnement-Santé environnement (AMES), University of La Rochelle , La Rochelle, France
| |
Collapse
|
748
|
Tiet P, Berlin JM. Exploiting homing abilities of cell carriers: Targeted delivery of nanoparticles for cancer therapy. Biochem Pharmacol 2017; 145:18-26. [PMID: 28941937 DOI: 10.1016/j.bcp.2017.09.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Accepted: 09/18/2017] [Indexed: 12/26/2022]
Abstract
Off target toxicities is one of the hallmarks of conventional chemotherapy as only a tiny percentage of the injected dose actually reaches the tumor(s). Numerous strategies have been employed in attempts to achieve targeted therapeutic delivery to tumors. One strategy that has received immense attention has been the packaging of these chemotherapeutics into nanoparticles and relying on the enhanced permeation and retention (EPR) effect for targeting. However, few, if any, nanoformulations have been used clinically that actually show enhanced drug delivery to tumors. There are a number of biological barriers to successful targeted delivery and nanoparticles large enough to theoretically benefit from the EPR effect predominantly accumulate in the liver and spleen after systemic administration. Nanoparticles that do reach the tumor will experience challenges such as difficulty penetrating deeply into tumors and rapid uptake by macrophages rather than tumor cells. In order to overcome this, researchers are investigating a new drug delivery system by utilizing T-cells, macrophages, or stem cells (Mesenchymal/Neural Stem Cells) and loading them with therapeutic nanoparticles for targeted delivery due to either their organotropic or tumor tropic migratory capabilities. By exploiting the migration and motility of these particular cells, researchers have delivered drug-loaded nanoparticles as well as nanoparticles for use in thermal ablation and magnetic field treatments, with the goals of decreasing off-target toxicities and increasing intratumoral distribution of the therapeutic payload. This is an inherently complex drug delivery system that requires optimization of multiple parameters - including cell type, payload, cell loading, release rate from nanoparticle and more - for success. Here we review recent advances and upcoming challenges for the field.
Collapse
Affiliation(s)
- Pamela Tiet
- Department of Molecular Medicine, Beckman Research Institute at City of Hope, 11500 East Duarte Road, Duarte, CA 91010, United States.
| | - Jacob M Berlin
- Department of Molecular Medicine, Beckman Research Institute at City of Hope, 11500 East Duarte Road, Duarte, CA 91010, United States.
| |
Collapse
|
749
|
Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O, Marzouk A, El Habak K, Mostafa R, Ali MA, Ellithy M. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother 2017; 95:1209-1218. [PMID: 28931213 DOI: 10.1016/j.biopha.2017.09.059] [Citation(s) in RCA: 181] [Impact Index Per Article: 25.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Revised: 09/04/2017] [Accepted: 09/12/2017] [Indexed: 12/28/2022] Open
Abstract
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various problems due to lack of selectivity with subsequent therapeutic failure and adverse effects. DOX- induced cardiotoxicity is a major problem that necessitates the presence of new forms to decrease the risk of associated morbidity. Nanoparticles (NPs) are considered an important approach to selectively increase drug accumulation inside tumor cells and thus decreasing the associated side effects. Tumor cells develop resistance to chemotherapeutic agents through multiple mechanisms, one of which is over expression of efflux transporters. Various NPs have been investigated to overcome efflux mediated resistance. To date, only liposomal doxorubicin (LD) and pegylated liposomal doxorubicin (PLD) have entered phase II and III clinical trials and FDA- approved for clinical use in MBC. This review addresses the effects of LD and PLD on the hematological and palmar-plantar erythrodysesthesia (PPE) in anthracycline naïve and pretreated MBC patients. For evidence, studies to be included in this review were identified through PubMed, Cochrane and Google scholar databases. The results derived from: four phase III clinical trials that compared LD with the conventional DOX in naïve MBC patients, and ten non-comparative clinical trials investigated LD and PLD as monotherapy or combination in pretreated MBC. This work confirmed the cardiac tolerability profile of LD and PLD versus DOX, while hematological and skin toxicities were more common. Other DOX-NPs in preclinical trials were discussed in a chronological order. Finally, the modern preclinical development framework for DOX includes exosomal DOX (exo-DOX). Exosomal NPs are non-toxic, non-immunogenic, and can be engineered to have high cargo loading capacity and targeting specificity. These NPs have not been investigated clinically. Our study shows that the full clinical potentiality of DOX-NPs remains to be addressed to move the field forward.
Collapse
Affiliation(s)
- Ayman Shafei
- Biomedical Research Department, Armed Forces College of Medicine, Cairo, Egypt
| | - Wesam El-Bakly
- Pharmacology Department, Faculty of Medicine, Ain Shams University, Egypt.
| | | | | | | | | | | | | | - Randa Mostafa
- Biomedical Research Department, Armed Forces College of Medicine, Cairo, Egypt
| | - Mahmoud A Ali
- Biomedical Research Department, Armed Forces College of Medicine, Cairo, Egypt
| | - Mahmoud Ellithy
- Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Egypt
| |
Collapse
|
750
|
Duro-Castano A, Gallon E, Decker C, Vicent MJ. Modulating angiogenesis with integrin-targeted nanomedicines. Adv Drug Deliv Rev 2017; 119:101-119. [PMID: 28502767 DOI: 10.1016/j.addr.2017.05.008] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2017] [Revised: 04/12/2017] [Accepted: 05/09/2017] [Indexed: 12/20/2022]
Abstract
Targeting angiogenesis-related pathologies, which include tumorigenesis and metastatic processes, has become an attractive strategy for the development of efficient guided nanomedicines. In this respect, integrins are cell-adhesion molecules involved in angiogenesis signaling pathways and are overexpressed in many angiogenic processes. Therefore, they represent specific biomarkers not only to monitor disease progression but also to rationally design targeted nanomedicines. Arginine-glycine-aspartic (RGD) containing peptides that bind to specific integrins have been widely utilized to provide ligand-mediated targeting capabilities to small molecules, peptides, proteins, and antibodies, as well as to drug/imaging agent-containing nanomedicines, with the final aim of maximizing their therapeutic index. Within this review, we aim to cover recent and relevant examples of different integrin-assisted nanosystems including polymeric nanoconstructs, liposomes, and inorganic nanoparticles applied in drug/gene therapy as well as imaging and theranostics. We will also critically address the overall benefits of integrin-targeting.
Collapse
Affiliation(s)
- Aroa Duro-Castano
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab., Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - Elena Gallon
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab., Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - Caitlin Decker
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab., Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - María J Vicent
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab., Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| |
Collapse
|